Valeant Upgraded To Overweight From Equal Weight At Barclays
June 06, 2018 at 09:54 AM EDT
Barclays analyst Douglas Tsao upgraded Valeant Pharmaceuticals to Overweight from Equal Weight and raised his price target for the shares to $29 from $20.
